QIAGEN Introduces QuantiFERON Monitor® for Tracking Immune Function in Solid Organ Transplant Patien
Published: Jan 27, 2015 4:00 p.m. ET
HILDEN, Germany, and GERMANTOWN, Maryland, January 27, 2015 /PRNewswire via COMTEX/ — HILDEN, Germany, and GERMANTOWN, Maryland, January 27, 2015 /PRNewswire/ —
QuantiFERON Monitor (QFM ® ) launches in Europe for monitoring immune function
Target markets include transplant patients and research in managing immune modulation and suppression
Novel diagnostic with significant potential to expand clinical utility and to address unmet medical need in more than 100,000 solid organ transplants a year
QFM applies proven QuantiFERON technology to deliver standardized, cost-effective measurement of immune function
QIAGEN N.V. QGEN, +0.39% (frankfurt prime standard:QIA) today announced the commercial launch of QuantiFERON Monitor® (QFM®), a novel diagnostic for monitoring immune function. QIAGEN is launching QuantiFERON Monitor in Europe as a CE-marked in-vitro diagnostic. Primary applications include monitoring of immune function in solid organ transplant recipients. In North America and other markets, QFM is available for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation. More than 100,000 patients a year worldwide undergo solid organ transplant surgery.